📗 Cite This Artifact
📖
RA Capital Management
active
wiki page
Created: 2026-04-02T07:20:10
By: crosslink-migration
Quality:
50%
✓ SciDEX
ID: wiki-institutions-ra-capital-management
📖 Wiki Page
institution1417 wordssynced 2026-04-02
Overview
flowchart TD
institutions_ra_capital_manage["RA Capital Management"]
style institutions_ra_capital_manage fill:#4fc3f7,stroke:#333,color:#000
institutions_ra_capi_0["Investment Focus"]
institutions_ra_capital_manage -->|"includes"| institutions_ra_capi_0
style institutions_ra_capi_0 fill:#81c784,stroke:#333,color:#000
institutions_ra_capi_1["Investment Thesis"]
institutions_ra_capital_manage -->|"includes"| institutions_ra_capi_1
style institutions_ra_capi_1 fill:#ef5350,stroke:#333,color:#000
institutions_ra_capi_2["Portfolio Companies"]
institutions_ra_capital_manage -->|"includes"| institutions_ra_capi_2
style institutions_ra_capi_2 fill:#ffd54f,stroke:#333,color:#000
institutions_ra_capi_3["Investment Strategy"]
institutions_ra_capital_manage -->|"includes"| institutions_ra_capi_3
style institutions_ra_capi_3 fill:#ce93d8,stroke:#333,color:#000
institutions_ra_capi_4["Impact on Neurodegeneration Research"]
institutions_ra_capital_manage -->|"includes"| institutions_ra_capi_4
style institutions_ra_capi_4 fill:#4fc3f7,stroke:#333,color:#000
institutions_ra_capi_5["Notable Portfolio Successes"]
institutions_ra_capital_manage -->|"includes"| institutions_ra_capi_5
style institutions_ra_capi_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
RA Capital Management is a specialized healthcare investment firm dedicated to building transformative medicines for patients. Founded in 2004, the firm has established itself as a leading investor in biotechnology companies focused on neurological diseases, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions["@ra2024"].
Investment Focus
RA Capital focuses on several key areas in neurodegeneration[@ra2024a]:
- Alzheimer's Disease: Companies developing disease-modifying therapies targeting amyloid-beta, tau, neuroinflammation, and synaptic dysfunction
- Parkinson's Disease: Investments in alpha-synuclein targeting therapies, LRRK2 inhibitors, and neuroprotective approaches
- Amyotrophic Lateral Sclerosis (ALS): Support for companies developing therapies for motor neuron diseases
- Rare Neurological Diseases: Investments in companies developing treatments for rare neurodegenerative conditions
- Novel Modalities: Including RNA therapeutics, gene therapy, and targeted protein degradation
Investment Thesis
RA Capital's investment approach is characterized by[@biocentury2024]:
Portfolio Companies
RA Capital has invested in numerous biotechnology companies developing treatments for neurodegenerative diseases[@crunchbase2024]:
- AC Immune: Company developing tau and amyloid-targeted immunotherapies for Alzheimer's disease
- ALX Oncology: Focused on CD47 checkpoint inhibitors with potential applications in neuroinflammation
- Axsome Therapeutics: Developing novel therapies for CNS disorders including Alzheimer's disease
- Biohaven Pharmaceutical: Focus on glutamate modulators and CGRP antagonists
- Caribou Biosciences: Developer of CRISPR-based therapies with potential neurological applications
- Cerevel Therapeutics: Focused on neuroscience drug development for Parkinson's and Alzheimer's
- Crinetics Pharmaceuticals: Peptide-based therapeutics with CNS applications
- Cytokinetics: Developing muscle-targeted therapies with relevance to neuromuscular conditions
- Denali Therapeutics: Focused on neurodegenerative disease therapeutics including LRRK2 and tau
- Entrada Therapeutics: Intracellular delivery platform for neurological diseases
- Grey Matter: Private company focused on microglia modulation for neurodegeneration
- Healx: AI-powered drug discovery for rare neurological diseases
- Immunovant: FcRn inhibitor with potential for autoimmune neurological conditions
- Intra-Cellular Therapies: Developer of lumateperone for CNS disorders
- JCR Pharmaceuticals: Focused on rare diseases including neurological manifestations
- Karyopharm Therapeutics: SINE compounds for neurodegenerative disease
- Lexicon Pharmaceuticals: Developer of neuropeptide-targeted therapies
- MabCare Therapeutics: Oncology-focused with pipeline expansion potential
- Melt Therapeutics: Developing novel pain and neurological disorder treatments
- Neurimmune: Antibody-based therapies for neurodegenerative diseases
- Nexo Therapeutics: Precision oncology with CNS applications
- Ovid Therapeutics: Focused on rare neurological disorders
- ProMIS Neurosciences: Targeting misfolded proteins in Alzheimer's and ALS
- Prothelia: Developing therapies for laminin-related neuromuscular conditions
- PTC Therapeutics: RNA-based therapeutics for neurological diseases
- Pyxis Oncology: Immuno-oncology with CNS penetration capabilities
- RareCyte: Diagnostic platforms for neurological disease
- Regenxbio: Gene therapy for neurological disorders
- Rejuvinex: Focused on cellular rejuvenation for age-related neurodegeneration
- Ribon Therapeutics: Developing novel therapeutics targeting stress pathways
- Soleno Therapeutics: RNA-targeted approaches for neurological diseases
- Stoke Therapeutics: RNAse-dependent approaches for neurological diseases
- Synlogic: Synthetic biology approaches to neurological disease
- Tallache Therapeutics: Focused on CNS disorders
- Theravance Biopharma: Multi-therapeutic area development
- Titan Pharmaceuticals: Long-acting therapeutics for neurological conditions
- Ventus Therapeutics: Structural biology approach to drug discovery
- Vikings Therapeutics: Novel therapeutics for neurodegenerative diseases
- Yumanity Therapeutics: Focused on protein aggregation in neurodegeneration
Investment Strategy
RA Capital employs a multi-stage investment strategy[@sec2024]:
- Seed Investments: Early-stage funding for novel therapeutic approaches
- Series A-B: Growth capital for companies with validated science
- Public Market Investments: Continued support for public companies in clinical development
- Cross-Fund Collaboration: Leveraging expertise across RA Capital's funds
Impact on Neurodegeneration Research
RA Capital has made significant contributions to advancing neurodegeneration research:
- Funding Innovation: Providing critical capital for early-stage biotech companies
- Clinical Development: Supporting companies through clinical trials and regulatory processes
- Partnership Facilitation: Connecting portfolio companies with pharmaceutical partners
- Expertise Sharing: Leveraging deep scientific and business expertise
Notable Portfolio Successes
RA Capital has achieved several notable exits in the neurodegeneration space:
- Axsome Therapeutics: Successfully brought novel CNS therapies through clinical trials
- Biohaven Pharmaceutical: Developed CGRP antagonists for migraine, with pipeline expansion into neurological diseases
- Cerevel Therapeutics: Advanced neuroscience-focused clinical programs
- Denali Therapeutics: Multiple clinical-stage programs in neurodegeneration
Investment Team and Expertise
RA Capital's investment team includes:
- Scientific Advisory Board: Leading academic researchers and former pharma executives
- Investment Professionals: Expertise across neuroscience, drug development, and healthcare
- Operating Partners: Former biotech CEOs and pharmaceutical executives who provide operational guidance
Partnership Model
RA Capital works closely with portfolio companies through:
Alzheimer's Disease Investment Focus
Amyloid-Targeting Companies
RA Capital has invested in multiple companies developing amyloid-targeted therapies:
- AC Immune: Developing tau and amyloid immunotherapies
- ProMIS Neurosciences: Targeting misfolded amyloid-beta oligomers
- Companies working on BACE inhibitors and anti-amyloid antibodies
Tau and Neurofibrillary Tangle Approaches
Investments in tau-targeting companies include:
- Companies developing tau aggregation inhibitors
- Tau immunotherapy programs
- Tau PET tracer development for diagnosis and monitoring
Neuroinflammation and Microglia
RA Capital recognizes neuroinflammation as a key therapeutic target:
- Grey Matter: Focused on microglia modulation
- Companies developing anti-inflammatory approaches for neurodegeneration
- Targets including TREM2, CD33, and other microglial receptors
Parkinson's Disease Investment Focus
Alpha-Synuclein Targeting
Investments in alpha-synuclein-focused companies:
- Aggregation inhibitors
- Antibody-based therapies
- Gene therapy approaches targeting alpha-synuclein
LRRK2 and Genetic Forms
RA Capital supports companies targeting genetic forms of Parkinson's:
- LRRK2 kinase inhibitors
- GBA1 modulators
- Gene therapy for inherited forms of PD
Neuroprotection and Disease Modification
Investment in neuroprotective approaches:
- Mitochondrial protectors
- Autophagy enhancers
- Synaptic function modulators
ALS and Motor Neuron Disease
Genetic Targets
RA Capital has invested in companies targeting:
- SOD1 (superoxide dismutase 1) mutations
- C9orf72 expansions
- FUS (fused in sarcoma) mutations
Symptomatic and Disease-Modifying Approaches
Investments span both symptomatic and disease-modifying therapies:
- Muscle-targeted therapies (Cytokinetics)
- RNA-based approaches
- Gene therapy programs
Rare Neurological Diseases
RA Capital invests in treatments for rare neurodegenerative conditions:
- PTC Therapeutics: RNA-based approaches for rare neurological diseases
- Regenxbio: Gene therapy for neurological disorders
- Prothelia: Therapies for laminin-related conditions
Investment Criteria for Rare Disease Companies
- Clear understanding of disease biology
- Validated therapeutic target
- Clear regulatory pathway
- Potential for accelerated approval
Industry Collaboration
Pharma Partnerships
RA Capital portfolio companies have established partnerships with major pharmaceutical companies:
- Roche/Genentech: Amyloid immunotherapy collaboration
- Biogen: Tau and alpha-synuclein programs
- Novartis: Various CNS programs
- Pfizer: Neuroscience research collaborations
Academic Collaborations
Many portfolio companies maintain active academic collaborations:
- University research partnerships
- Clinical trial site relationships
- Consortium participation
Due Diligence Process
Scientific Evaluation
RA Capital's due diligence process includes:
Team Evaluation
Assessment of company leadership:
- Track record of drug development
- Scientific expertise
- Operational capabilities
- Financial management
Future Investment Directions
Emerging Modalities
RA Capital continues to identify emerging therapeutic modalities:
- RNA Therapeutics: ASOs, siRNA, and mRNA-based approaches
- Gene Therapy: AAV delivery and gene editing
- Protein Degradation: PROTACs and molecular glues
- Cell Therapy: Stem cell and cell replacement approaches
Biomarker Development
Investment in biomarker companies for:
- Patient stratification
- Clinical trial enrichment
- Treatment response monitoring
Digital Health
Supporting companies developing:
- Digital biomarkers
- Remote monitoring platforms
- AI-powered diagnostics
Metrics and Track Record
Portfolio Statistics
RA Capital's neurodegeneration portfolio includes:
- 40+ companies with active CNS programs
- Multiple Phase 2 and Phase 3 clinical trials
- Several FDA approvals in neuroscience indications
Value Creation
The firm has demonstrated ability to:
- Identify high-potential therapeutic targets
- Build companies from early stages to clinical maturity
- Achieve successful exits through M&A and IPOs
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Neurodegeneration](/diseases/neurodegeneration)
- [Dementia Discovery Fund](/institutions/dementia-discovery-fund)
- [ARCH Venture Partners](/institutions/arch-venture-partners)
- [Versant Ventures](/institutions/versant-ventures)
- [Google Ventures (GV)](/institutions/google-ventures)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Pathway Diagram
The following diagram shows the key molecular relationships involving RA Capital Management discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Related Entities
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | institutions-ra-capital-management |
| kg_node_id | None |
| entity_type | institution |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-bfad92654a9b |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-ra-capital-management'} |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
30%
Debates
0
Incoming
6
Outgoing
29
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
1 nodes, 0 edges
No provenance edges found
This artifact has no version history yet.
Linked Artifacts (35)
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/wiki-institutions-ra-capital-management?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[RA Capital Management](http://scidex.ai/artifact/wiki-institutions-ra-capital-management)
Direct URL
http://scidex.ai/artifact/wiki-institutions-ra-capital-management
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.